Segment, Geographic and Other Revenue Information - Revenues by Products (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2024	Oct. 01, 2023	Sep. 29, 2024	Oct. 01, 2023
Revenue from External Customer [Line Items]
Revenues:		$ 17,702	$ 13,491	$ 45,864	$ 44,984
Alliance revenues	[1]	1,900	1,645	6,140	5,672
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		17,392	13,188	44,987	44,051
Biopharma [Member] | U.S. Commercial Division [Member]
Revenue from External Customer [Line Items]
Revenues:		8,938	5,864	20,702	16,679
Biopharma [Member] | Oncology Division [Member]
Revenue from External Customer [Line Items]
Revenues:		3,026	2,111	8,516	6,260
Biopharma [Member] | International Commercial Division [Member]
Revenue from External Customer [Line Items]
Revenues:		5,428	5,214	15,769	21,112
Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues:	[2]	285	293	820	908
Pfizer Ignite [Member]
Revenue from External Customer [Line Items]
Revenues:		25	10	56	25
Total Alliance revenues [Member]
Revenue from External Customer [Line Items]
Alliance revenues		1,900	1,645	6,140	5,672
Royalty revenues
Revenue from External Customer [Line Items]
Royalty revenue	[1]	384	260	992	737
Primary Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		9,060	6,310	21,224	23,755
Primary Care [Member] | Eliquis [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[3]	1,617	1,498	5,534	5,135
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[4]	2,703	202	4,989	4,414
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,803	1,843	4,853	4,877
Primary Care [Member] | Comirnaty [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,422	1,306	1,970	5,858
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		337	233	870	646
Primary Care [Member] | Abrysvo [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		356	375	557	375
Primary Care [Member] | Premarin family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		90	92	283	299
Primary Care [Member] | FSME-IMMUN/TicoVac [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		81	91	246	237
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		652	670	1,921	1,914
Specialty Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		4,289	3,763	12,215	11,035
Specialty Care [Member] | Vyndaqel family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,447	892	3,907	2,360
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		321	503	818	1,210
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		169	208	507	627
Specialty Care [Member] | Sulperazon [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		156	122	468	619
Specialty Care [Member] | Zavicefta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		152	130	427	378
Specialty Care [Member] | Octagam [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[5]	221	53	400	164
Specialty Care [Member] | Inflectra [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		126	121	382	373
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		119	158	358	379
Specialty Care [Member] | Zithromax [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		83	60	357	254
Specialty Care [Member] | BeneFIX [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		88	107	294	321
Specialty Care [Member] | Oxbryta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[6]	17	85	193	232
Specialty Care [Member] | Cibinqo [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		63	37	152	91
Specialty Care [Member] | All other Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[7]	1,108	1,086	3,296	3,452
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		218	202	658	575
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		4,043	3,115	11,549	9,261
Oncology [Member] | Ibrance [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,087	1,244	3,272	3,635
Oncology [Member] | Xtandi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[8]	561	440	1,474	1,202
Oncology [Member] | Padcev [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		409	0	1,144	0
Oncology [Member] | Oncology Biosimilars [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[9]	285	310	828	1,085
Oncology [Member] | Adcetris [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		268	0	804	0
Oncology [Member] | Inlyta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		247	252	736	773
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		206	159	538	393
Oncology [Member] | Bosulif [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		161	160	474	463
Oncology [Member] | Braftovi/Mektovi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[10]	173	131	437	346
Oncology [Member] | Tukysa [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		124	0	351	0
Oncology [Member] | Tivdak [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		34	0	94	0
Oncology [Member] | Talzenna [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		36	20	91	42
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		$ 453	$ 399	$ 1,306	$ 1,322

[1] See Note1A.

[2] PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.

[3] Primarily reflects Alliance revenues and product revenues.

[4] The third quarter and first nine months of 2024 includes $442 million of revenue recorded in connection with the creation of the U.S. SNS. The first nine months of 2024 also includes a $771 million favorable final adjustment recorded in the first quarter of 2024 to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023.

[5] The third quarter and first nine months of 2024 include $129 million related to a one-time sales true-up settlement agreement with our commercialization partner.

[6] In September 2024, we announced our voluntary withdrawal of all lots of Oxbryta for the treatment of sickle cell disease in all markets where it is approved, as well as the discontinuation of all active voxelotor clinical trials and expanded access programs worldwide, based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events, which requires further assessment.

[7] Includes, among other Hospital products, amounts previously presented as All other Anti-infectives and Ig Portfolio.

[8] Primarily reflects Alliance revenues and royalty revenues.

[9] Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym.

[10] Erbitux is a registered trademark of ImClone LLC.